Akeso Inc. announced the enrollment of the first patient in the registrational Phase III clinical study comparing Cadonilimab combined with chemotherapy versus Tislelizumab combined with chemotherapy in the first-line treatment for patients with PD-L1 negative non-small cell lung cancer.
